During this episode, Lynora Saxinger, MD, FRCPC, CTropMed, updates listeners on the latest Emergency Use Authorizations and guideline recommendations for optimal clinical management of COVID-19. Gain practical insights on patient identification, risk stratification, and treatment.

Key points include:

• Treatment of COVID-19 can be broken into antiviral and immune-modulating therapies
• Each agent should be used at the correct disease stage to maximize benefit
• Antiviral medications and mAbs show the greatest promise early during COVID-19, before the host immune response is mounted
• Passive immunization with mAbs can prevent infection and severe disease—and mortality—if given early to hospitalized persons
• Operational challenges to using these medications exist, but given the epidemic of unvaccinated persons, these treatments become increasingly relevant to reduce burden on healthcare systems

Presenter:

Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta, Canada

Content based on an online CME program supported by an educational grant from Gilead Sciences, Inc.

Follow along with the slides at:
https://bit.ly/3BxQKtD

Link to full program:
https://bit.ly/3BwzdlC